[HTML][HTML] PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …
processes, including the regulation of transcription, apoptosis and the DNA damage …
[HTML][HTML] BRCA mutations in ovarian and prostate cancer: bench to bedside
Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …
TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved
for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic …
for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic …
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …
NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines
E Schaeffer, S Srinivas, ES Antonarakis… - Journal of the National …, 2021 - jnccn.org
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …
prostate cancer diagnosis and include management options for localized, regional, and …
Olaparib for metastatic castration-resistant prostate cancer
Background Multiple loss-of-function alterations in genes that are involved in DNA repair,
including homologous recombination repair, are associated with response to poly …
including homologous recombination repair, are associated with response to poly …
Survival with olaparib in metastatic castration-resistant prostate cancer
Background We previously reported that olaparib led to significantly longer imaging-based
progression-free survival than the physician's choice of enzalutamide or abiraterone among …
progression-free survival than the physician's choice of enzalutamide or abiraterone among …
Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the …
Purpose: Genomic alterations in DNA damage repair (DDR) genes other than BRCA may
confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate …
confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate …
[HTML][HTML] A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
JJ Gruber, A Afghahi, K Timms, A DeWees, W Gross… - Nature Cancer, 2022 - nature.com
Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (g BRCA1/2)-mutant
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …
NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines
MB Daly, R Pilarski, MB Yurgelun, MP Berry… - Journal of the National …, 2020 - jnccn.org
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic provide recommendations for genetic testing and counseling for hereditary …
Pancreatic provide recommendations for genetic testing and counseling for hereditary …